AU2018204860A1 — Inhalable medicaments
Assigned to Pharmachemie BV · Expires 2018-07-19 · 8y expired
What this patent protects
Abstract The present invention provides a dry powder inhaler comprising: a reservoir containing a dry powder formulation and an arrangement for delivering a metered dose of the medicament from the reservoir; 5 a cyclone deagglomerator for breaking up agglomerates of the dry powde…
USPTO Abstract
Abstract The present invention provides a dry powder inhaler comprising: a reservoir containing a dry powder formulation and an arrangement for delivering a metered dose of the medicament from the reservoir; 5 a cyclone deagglomerator for breaking up agglomerates of the dry powder medicament; and a delivery passageway for directing an inhalation-induced air flow through a mouthpiece, the delivery passageway extending to the metered dose of medicament, wherein the formulation comprises an inhalable P2-agonist having a particle size distribution of d1 0 <1 pm, d50 = 1-3 pm, d90 = 3.5-6 pm and NLT 99% <10 pm and a lactose carrier. 10427867_2 (GHMatters) P103411.AU.1 WO 2015/086278 PCT/EP2014/075058 o~C b CD (. - CO C O CD -r- (N %l T- sO) uo(D ili CWfO CO!1CDfC)fCD
Drugs covered by this patent
- Cutivate (FLUTICASONE PROPIONATE) · Teva Pharm
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.